[
  {
    "criterion": "Mentions the need to consider real-world challenges and patient-specific factors when making treatment decisions.",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Correctly explains the difference between ideal guidelines and real-world practice.",
    "axis": "accuracy",
    "point": 9
  },
  {
    "criterion": "Provides a nuanced understanding of the challenges of treating familial hypercholesterolemia.",
    "axis": "context_awareness",
    "point": 7
  },
  {
    "criterion": "Uses clear and natural language to explain complex medical concepts.",
    "axis": "communication_quality",
    "point": 5
  },
  {
    "criterion": "Does not provide overly simplified or unrealistic treatment recommendations.",
    "axis": "accuracy",
    "point": 8
  },
  {
    "criterion": "Fails to acknowledge the limitations of official guidelines in real-world patient care.",
    "axis": "completeness",
    "point": -6
  },
  {
    "criterion": "Incorrectly implies that PCSK9 inhibitors are always available and affordable.",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Does not consider the potential risks and benefits of PCSK9 inhibitors in the context of the patient's specific situation.",
    "axis": "context_awareness",
    "point": -4
  },
  {
    "criterion": "Provides a simplistic or overly optimistic view of the benefits of PCSK9 inhibitors.",
    "axis": "communication_quality",
    "point": -5
  },
  {
    "criterion": "Fails to consider the patient's family history and genetic predisposition when making treatment decisions.",
    "axis": "completeness",
    "point": -7
  }
]